Bidirectionality of cardiovascular risk factors in patients with urolithiasis: current state of the problem


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The most common risk factors for cardiovascular disease and urolithiasis are presented in the article. Data on the prevalence of urolithiasis are discussed, as well as the pathogenetic mechanisms of stone formation in patients with metabolic syndrome, dyslipidemia, and arterial hypertension. The bi-directional relationship of cardiovascular risk factors and urolithiasis is generalized. The role of calcium, uric acid, citrate, changes in urine pH and an increase in body weight in the formation of kidney stones is shown

Full Text

Restricted Access

About the authors

I. T Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy

Ph.D., acting associate professor of Department of Faculty Internal Medicine Bishkek, Kyrgyzstan

K. A Aitbaev

Research Institute of Molecular Biology and Medicine

Email: kaitbaev@yahoo.com
Ph.D., MD, professor, Head of the Laboratory of Pathophysiology Bishkek, Kyrgyzstan

V. V Fomin

I.M. Sechenov First Moscow State Medical University

Email: fomin_vic@mail.ru
Ph.D., MD, professor, corresponding member of RAS, Head of the Department of Faculty Internal Medicine №1 Moscow, Russia

Zh. A Murkamilova

Kyrgyz Russian Slavic University

Email: murkamilovazh.t@mail.ru
correspondence Ph.D. student at the Department of Internal Medicine No2 Bishkek, Kyrgyzstan

F. A Yusupov

Osh State University

Email: furcat_y@mail.ru
Ph.D., MD, professor, Head of the Department of Neurology, Neurosurgery and Psychiatry Faculty of Medical Faculty Osh, Kyrgyzstan

A. I Schastlivenko

Vitebsk State Order of Peoples Friendship Medical University

Email: andrei.schastlivenko@mail.ru
Ph.D., associate professor of Department of General Practitioner with a course of polyclinic therapy Vitebsk, Belarus

References

  1. Пепенин В.Р., Спиридоненко В.В., Комаревцев В.Н., Беличенко О.В., Пепенин С.В. Роль цитратной терапии при лечении уратного уролитиаза с помощью малоинвазивных технологий. Здоровье мужчины. 2011 ;4:140-147
  2. Türk C., Petnk A., Sarica K., et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. Eur Urol.2016;69(3):468-474. https://doi.org/10.1016/j.eururo.2015.07.040
  3. William J. H. Epidemiology of kidney stones in the United States. Nutritional and Medical Management of Kidney Stones. Humana. Cham. 2019. С. 3-17. https://doi.org/10.1007/978-3-030-15534-6_1
  4. Evan A.P. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr. Nephrol. 2010;25:5:831-841. https://doi.org/10.1007/s00467-009-1116-y
  5. Россоловский А.Н., Березинец О.Л., Блюмберг Б.И. Мочекаменная болезнь: эволюция представлений (обзор). Бюллетень медицинских интернет-конференций. Общество с ограниченной ответственностью «Наука и инновации». 2014;4(1):84- 86.
  6. Trinchieri A. Epidemiology of urolithiasis: an update. Clinical cases in mineral and bone metabolism.2008;5:2:101-106. PMID: 22460989.
  7. Romero V., Akpinar H., Assimos D.G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-e96. PMID: 20811557.
  8. Turney B.W., Reynard J.M., Noble J.G., Keoghane S.R. Trends in urological stone disease. BJU Int.2012;109(7):1082-1087. https://doi.org/10.1111/j.1464-410X.2011.10495.x
  9. Akoudad S., Szklo M., McAdams M.A., et al. Correlates of kidney stone disease differ by race in a multi-ethnic middle aged population: The ARIC Study. Prev Med. 2010;51(5):416-420. https://doi.org/10.1016/j.ypmed.2010.08.011
  10. Wändell P., Carlsson A.C., Li X., et al. Urolithiasis in second-generation immigrant children younger than 18 years of age in Sweden. Acta Paediatrica.2020. https://doi.org/10.1111/apa.15298
  11. Alexander R.T., Hemmelgarn B.R., Wiebe N., et al. Kidney stones and cardiovascular events: a cohort study. Clinical Journal of the American Society of Nephrology. 2014;9:3:506-512. Doi: https://doi.org/10.2215/CJN.04960513
  12. Aviram M. Atherosclerosis: cell biology and lipoproteins - paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol. 2012;23(2):169-171. https://doi.org/10.1097/MOL.0b013e3283513594
  13. Menon M., Resnick M.I. Urinary lithiasis: etiology, diagnosis, and medical management In: Campbell’s Urology, 8th Ed. WB Saunders Company: Philadelphia. PA. 2002. С. 3242-3305.
  14. Gaharwar Y.S., Topale S.S., Farouqi U., Prakash B.S. Role of atherosclerosis in pathogenesis of renal stone disease: Do all roads lead to Rome?. J Mahatma Gandhi Inst Med Sci. 2017;22:4-7. https://doi.org/10.4103/0971-9903.202014
  15. Skolarikos A., Straub M., Knoll T., et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750-763. https://doi.org/10.1016/j.eururo.2014.10.029
  16. Lin S.K., Liu J.M., Chang Y.H., et al. Increased risk of endotracheal intubation and heart failure following acute myocardial infarction in patients with urolithiasis: a nationwide population-based study Ther Clin Risk Manag.2017;13:245-253. https://doi.org/10.2147/TCRM.S123702
  17. Ernandez T., Bonny O. Kidney stone as a cardiovascular risk marker. Rev Med Suisse 2014;10(441):1656-1660. PMID: 25322624.
  18. Kim S.Y., Song C.M., Bang W., et al. Nephrolithiasis predicts ischemic stroke: A longitudinal follow-up study using a national sample cohort. International journal of medical sciences.2019;16:8:1050-1056. https://doi.org/10.7150/ijms.34417
  19. Mackness M.I., Durrington P.N., Ayub A., Mackness B. Low serum paraoxonase: a risk factor for atherosclerotic disease? Chem Biol Interact. 1999;14:119-120:389-397. https://doi.org/10.1016/s0009-2797(99)00050-2
  20. Lai C.H., Huang L.C., Holby S.N., et al. Kidney stone history and adverse outcomes after percutaneous coronary intervention. Urology.2020;136:75-81. https://doi.org/10.1016/j.urology.2019.10.009
  21. Роюк Р.В., Яровой С.К., Гусева Н.А. и др. Эпидемиологические аспекты сочетания нефролитиаза и хронических заболеваний сердечно-сосудистой системы. Исследования и практика в медицине. 2020;7(1):38-47. https://doi.org/10.17709/2409-2231-2020-7-1-4
  22. Жариков А.Ю., Брюханов В.М., Зверев Я.Ф., Лампатов В.В. Современные методы моделирования оксалатного нефролитиаза. Нефрология. 2008; 12(4):28-35. https://doi.org/10.24884/1561-6274-2008-12-4-28-35
  23. Муркамилов И.Т., Айтбаев К.А., Фомин В.В., Юсупов Ф.А., Счастливенко А.И. Инсульт у пациентов с мочекаменной болезнью: распространенность и факторы риска. The Scientific Heritage. 2020;47(2):40-44
  24. Rosa D., Villa G., Montanari E., et al. The relationship between urolithiasis, metabolic syndrome and nurse shift work. A literature review.International Journal of Urological Nursing.2020. https://doi.org/10.1111/ijun.12233
  25. Тызьо Д.В., Ахназарян М.С., Макеева А.В. Сравнительная оценка факторов риска в патогенезе развития мочекаменной болезни почек. Научное обозрение. Педагогические науки.2019;5:115-119
  26. Lee Y.C., Huang S.P., Juan Y.S., Huang T.Y., Liu C.C. Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males. Aging Male. 2016;19(3):197-201. https://doi.org/10.1080/13685538.2016.1174987
  27. Cho S.T., Jung S.I., Myung S.C., Kim T.H. Correlation of metabolic syndrome with urinary stone composition. Int J Urol. 2013;20: 208-213. https://doi.org/10.1111/j.1442-2042.2012.03131.x
  28. Arafa A., Eshak E.S., Iso H. Oxalates, Urinary Stones and Risk of Cardiovascular Diseases. Medical Hypotheses. 2020.С. 109570. https://doi.org/10.1016/j.mehy.2020.109570
  29. Domingos F., Serra A. Metabolic syndrome: a multifaceted risk factor for kidney stones. Scand J Urol. 2014;48(5):414-419. https://doi.org/10.3109/21681805.2014.903513
  30. Лелявин К.Б., Селиверстова Т.Г., Рева А.А. Мочекаменная болезнь как новый компонент «метаболически здорового» ожирения. Современные проблемы науки и образования. 2019.4.URL: http:// www.science-education.ru/ru/article/view?id=29075 (дата обращения: 17.05.2020).
  31. Cupisti A, Meola M, DAlessandro C., et al. Insulin resistance and lowurinary citrate excretion in calcium stone formers. Biomed Pharmacother.2007;61(1):86-90. https://doi.org/10.1016/j.biopha.2006.09.012
  32. Taylor E.N., Mount D.B., Forman J.P., Curhan G.C. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis. 2006;47(5):780-789. https://doi.org/10.1053/j.ajkd.2006.01.024
  33. Wrobel B.M., Wrobel B., Hormann M., Strohmaier W.L. Overweight and obesity: risk factors in calcium oxalate stone disease? Adv Urol.2012;2012:438707. https://doi.org/10.1155/2012/438707
  34. Аляев Ю.Г., Кузьмичева Г.М., Руденко В.И. Современные аспекты цитратной терапии у больных мочекаменной болезнью. Врачебное сословие. 2004;4:20-24.
  35. Медведев В.Л., Татевосян А.С., Дмитренко Г.Д., и др. Комбинированное лечение больного с коралловидным камнем почки. Клинический случай. Инновационная медицина Кубани. 2019;(1):36-43
  36. Geraghty R., Abdi A., Somani B., Cook P., Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ open. 2020;10:1. http://dx.doi.org/10.1136/bmjopen-2019-032094
  37. Hernandez-Baixauli J., Quesada-Vazquez S., Marine-Casado R., et al. Detection of Early Disease Risk Factors Associated with Metabolic Syndrome: A New Era with the NMR Metabolomics Assessment.Nutrients. 2020;12:3:806. https://doi.org/10.3390/nu12030806
  38. Ding Q., Ouyang J., Fan B., et al. Association between Dyslipidemia and Nephrolithiasis Risk in a Chinese Population. Urologia internationalis. 2019;103:2:156-165. https://doi.org/10.1159/000496208
  39. Гаджиев Н.К., Малхасян В.А., Мазуренко Д.А. и др. Мочекаменная болезнь и метаболический синдром. Патофизиология камнеобразования. Экспериментальная и клиническая урология.2018;1:66-75. https://doi.org/10.29188/2222-8543-2018-9-1-66-75
  40. Kabeya Y., Kato K., Tomita M., et al. Associations of insulin resistance and glycemic control with the risk of kidney stones. Intern Med.2012;51:699- 705. https://doi.org/10.2169/internalmedicine.51.6426
  41. Голованов С.А., Просянников М.Ю., Анохин Н.В., Сивков А.В., Аполихин О.И. Функциональное состояние клеточных мембран у больных мочекаменной болезнью. Экспериментальная и клиническая урология. 2019;2:87-91. https://doi.org/10.29188/2222-8543-2019-11-2-87-91
  42. Yanagawa K., Takeda H., Egashira T., et al. Age-related changesin alpha-tocopherol dynamics with relation to lipid hydroperoxide content and fluidity of rat erythrocyte membrane. J Gerontol A Biol Sci Med Sci. 1999;54(9):B379-B783. https://doi.org/10.1093/gerona/54.9.B379
  43. Kirejczyk J.K., Korzeniecka-Kozerska A., Baran M., et al. Dyslipidaemia in overweight children and adolescents is associated with an increased risk of kidney stones. Acta Paediatr.2015;104(9):e407-413. https://doi.org/10.1111/apa.13079
  44. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1): 6-31. https://doi.org/10.26442/2075082X.2019.1.190179
  45. Ljunnghall S., Hedstrand H. Renal stones and coronary heart disease. BMJ. 1976;4:5996. ID 580. https://doi.org/10.1136/bmj.4.5996.580-a
  46. Robertson W.G., Peacock M., Baker M. et al. Studies on the prevalence and epidemiology of urinary stone disease in man in Leeds. Br. J. Urol. 1983;55:6:595-598. https://doi.org/10.1111/j.1464-410X.1983.tb03383.x
  47. Shang W., Li Y., Ren Y., et al. Nephrolithiasis and risk of hypertension: a meta-analysis of observational studies. BMC nephrology.2017;18:1:344. https://doi.org/10.1186/s12882-017-0762-8
  48. Батько А.Б. Патологические паттерны артериальной гипертензии и мочекаменной болезни. Эффективная фармакотерапия. 2019;15:29:12-15. https://doi.org/10.33978/2307-3586-2019-15-29-12-15
  49. Asplin J.R., Mandel N.S., Coe F.L. Evidence of calcium phosphate super saturation in the loop of Henle. Am J Physiol.1996;270(4 Pt 2):F604-F613. https://doi.org/10.1152/ajprenal.1996.270.4.F604
  50. Kum F., Wong K., Game D., et al. Hypertension and renal impairment in patients with cystinuria: findings from a specialist cystinuria centre.Urolithiasis. 2019;47:4:357-363. https://doi.org/10.1007/s00240-019-01110-8
  51. Ferraro P.M., Bargagli M., Trinchieri A., Gambaro G. Risk of Kidney Stones: Influence of Dietary Factors, Dietary Patterns, and Vegetarian-Vegan Diets. Nutrients. 2020; 12:3:779. https://doi.org/10.3390/nu12030779
  52. Rendina D., De Filippo G., D’Elia L., Strazzullo P. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J Nephrol. 2014;27(4):371-376. https://doi.org/10.1007/s40620-014-0085-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies